Research does not estimate vaccine effectiveness against hospitalisation, severe disease, and death. Two doses of Covaxin, the India-made vaccine, are 50 per cent effective against symptomatic Covid-19, said an independent study by researchers based on real-world assessment . Results of the interim study, which was published in The Lancet Infectious Diseases Journal, showed that two doses of the vaccine manufactured by Bharat Biotech Covaxin , also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.. The study titled ‘Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study’ assessed 2714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15–May 15, who were symptomatic and underwent RT-PCR test for Covid-19 detection. The researchers, including doctors Manish Soneja, Adil Rashid Khan, Devashish Desai,...